Our data indicate that phosphorylated and deacetylated STAT3 activates HLX which in turn inhibits BCL2L11 expression, representing a novel mechanism of BCL2L11 suppression in DLBCL. The gene discussed is STAT3; the disease is diffuse large B-cell lymphoma.